Core Viewpoint - 康方生物 reported strong mid-year performance with significant revenue growth driven by new product approvals and inclusion in national insurance directory [1] Financial Performance - The company achieved a revenue of 1.412 billion RMB in the first half of the year, representing a year-on-year increase of 37.75% [1] - Gross profit reached 1.121 billion RMB, up 18.82% compared to the previous year [1] - Commercial sales revenue was approximately 1.402 billion RMB, a 49.20% increase from 939 million RMB in the same period last year [1] Product Developments - The sales growth was primarily attributed to the inclusion of 开坦尼 (卡度尼利, PD-1/CTLA-4) and 依达方 (依沃西, PD-1/VEGF) in the national insurance directory, as well as new first-line indications [1] - The company successfully launched two new products, 伊喜宁 (伊努西, PCSK9) and 爱达罗 (依若奇, IL-12/IL-23), which have begun commercial sales [1] Regulatory Approvals - 依沃西单抗 (AK112) received approval from the National Medical Products Administration in May 2024 for use in treating locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) [1] - The Phase III HARMONi-A study (AK112-301) demonstrated statistically and clinically significant overall survival benefits, with detailed data to be presented at future international academic conferences [1]

Core Viewpoint - 康方生物 reported strong mid-year performance with significant revenue growth driven by new product approvals and inclusion in national insurance directory [1] Financial Performance - The company achieved a revenue of 14.12 billion RMB in the first half of the year, representing a year-on-year increase of 37.75% [1] - Gross profit reached 11.21 billion RMB, up 18.82% compared to the previous year [1] - Commercial sales revenue was approximately 14.02 billion RMB, a 49.20% increase from 9.39 billion RMB in the same period last year [1] Product Developments - The sales growth was primarily attributed to the inclusion of 开坦尼 (卡度尼利, PD-1/CTLA-4) and 依达方 (依沃西, PD-1/VEGF) in the national insurance directory, as well as new first-line indications [1] - The company successfully launched two new products, 伊喜宁 (伊努西, PCSK9) and 爱达罗 (依若奇, IL-12/IL-23), which have started to generate sales [1] Regulatory Approvals - 依沃西单抗 (AK112) is expected to receive approval from the National Medical Products Administration in May 2024 for treating locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC) [1] - The Phase III HARMONi-A study (AK112-301) has met its overall survival (OS) clinical endpoint, showing statistically and clinically significant OS benefits, with detailed data to be presented at future international academic conferences [1]